

BIOSECURE Act (FY2026 NDAA, Section 851): One-Page Readiness Checklist

Disclaimer: This checklist is provided for informational and planning purposes only and does not constitute legal advice. Compliance obligations under Section 851 of the FY2026 NDAA are subject to future OMB guidance and FAR implementation.

Conduct a Comprehensive Risk Assessment to Identify Current State (Start Immediately – Target Completion by Mid-2026)

- Map all biotechnology equipment/services providers (e.g., sequencing, CDMO, data storage/analysis).
- Identify any ties to potential BCCs
- Evaluate exposure to multiomic data handling and foreign adversary risks.
- Review existing contracts for grandfathering eligibility.

Monitor BCC Designations and Regulatory Developments (Ongoing – Critical Milestone: December 2026)

- Track DoD 1260H list updates (annual) and OMB BCC list (initial expected Dec 2026, then annual).
- Subscribe to federal registers/ notices for designations.

Develop a Diversification and Mitigation Plan (By End of 2026)

- Identify alternative suppliers (non-BCC).
- Negotiate termination/transition rights in existing agreements.
- Plan for 5-year grandfathering window if applicable.

Update Policies, Procedures, and Training (By Mid-2027)

- Establish due diligence processes for suppliers.
- Update compliance policies for FAR-covered contracts/grants.
- Prepare certifications of non-use of BCC equipment/services.
- Train procurement/legal teams on requirements.
- Maintain records for audits/compliance verification.

Prepare for Waivers, Exceptions, and Reporting (Ongoing)

- Document cases for potential waivers (e.g., overseas operations, emergencies).
- Identify qualifying exceptions (e.g., public multiomic data).

Conduct Ongoing Reviews and Adjustments (Annually Post-2027)

- Annual review of supply chain post-FAR amendment (~2028 effective dates).
- Report changes if receiving federal funds.